Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Hands Off Accelerator Program to Illumina Ventures

NEW YORK – Illumina Ventures said on Tuesday that it will be assuming control of the Illumina Accelerator program and rebranding it as Illumina Ventures Labs.

"Building on the foundation of the Illumina Accelerator program, Illumina Ventures Labs will operate and provide access to fully equipped genomics labs in the US and the UK, mentorship, and seed financing to attract a broad range of genomics related startups," Illumina Ventures said in a statement. Illumina will provide the startups with technical guidance and provide access to next-generation sequencing technology.

Financial and other terms of the deal were not disclosed.

Launched in 2014, the Illumina Accelerator provides select startups with undisclosed amounts of seed funding and access to genomics labs in either the San Francisco Bay Area or in Cambridge, UK.

Illumina Ventures, founded in 2016, is an independently managed venture capital firm. Illumina participates in the fund, but the majority of capital has been raised from other partners.

"This expansion of our relationship with Illumina is a continuation of Illumina Ventures' strategy to pursue earlier stage investing," Nick Naclerio, founding partner of Illumina Ventures, said in a statement. "The program will give early-stage companies a jump-start and accelerate timelines to the next value inflection point while providing additional investment opportunities for our fund."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.